GSK announces Board appointments to Haleon in conjunction with spin-off of GSK Consumer Healthcare division

– UK, Brentford –  GlaxoSmithKline plc (LON: GSK |NYSE: GSK) today announced the appointments of six directors to the designated Board of Haleon, the newly independent company to be formed following the demerger of the GSK Consumer Healthcare business, expected in July 2022.

Haleon will be a new global-leading company in Consumer Health and is strongly positioned to deliver better everyday health, sustainable above-market growth, and attractive returns to shareholders.

The new Board appointments follow the appointment of Sir Dave Lewis as Chair Designate in December 2021 and represent further progress to create a new, qualified Board for Haleon with the appropriate mix of skills, experience, diversity, and continuity.

The appointments include the transition of two GSK Non-Executive Directors and three new external appointees.

In addition, it is also confirmed that Tobias Hestler, CFO Designate, Haleon, will join Brian McNamara, CEO Designate, Haleon, on the Board as an Executive Director.

Appointments to Designate Haleon Board:

  • Vindi Banga will become Senior Independent Non-Executive Director. Vindi is currently Senior Independent Non-Executive Director of GSK.
  • Tracy Clarke will become an independent Non-Executive Director and Chair of the Remuneration Committee.
  • Dame Vivienne Cox will become an independent Non-Executive Director. Vivienne is currently an independent Non-Executive Director at GSK.
  • Deirdre Mahlan will become an independent Non-Executive Director and Chair of the Audit & Risk Committee.
  • John Young has been nominated as a Non-Executive Director by Pfizer as one of its two appointees under our joint venture arrangements. John is currently a director of the GSK/Pfizer Consumer Healthcare Joint Venture company.
  • Tobias Hestler, CFO Designate, Haleon, will become an Executive Director.

Vindi and Vivienne will remain on the GSK Board until demerger. Tobias is expected to be appointed a director of Haleon before the demerger. All the other appointments announced today will become effective from the demerger.

Vindi, Tracy, Vivienne, and Deidre are expected to be determined to be independent Non-Executive Directors of Haleon.

Sir Dave Lewis, Chair Designate, Haleon, said: “We are delighted to be welcoming Vindi, Tracy, Vivienne, Deirdre, and John as Non-Executive Directors to the future Board of Haleon. Together they bring considerable Board experience to support Haleon as a publicly listed company. They will also add an in-depth understanding of the global consumer sector, with particular experience operating in the US, China, India, and Europe. This is a significant step forward in creating the Haleon Board… It is an exciting time for everyone at Haleon and I look forward to working with new board colleagues to support Brian and his team to unleash the potential of this unique business.”

About Manvinder Singh (Vindi) Banga

Vindi is currently Senior Independent Director at GSK. He has been Chairman of UK Government Investments Limited (UKGI) since September 2021.

Vindi has many years of commercial experience and a track record of delivering outstanding performance in highly competitive global consumer-focused businesses. Vindi spent 33 years at Unilever plc, where his last role was President of the Global Foods, Home and Personal Care businesses, and a member of the Unilever Executive Board. Vindi sat on the Prime Minister of India’s Council of Trade & Industry from 2004 to 2014 and was on the Board of Governors of the Indian Institute of Management (IIM), Ahmedabad.

His prior non-executive roles include Non-Executive Director of the Confederation of British Industry (CBI) and Thomson Reuters Corp, Chairman of the Supervisory Board of Mauser Group, Chairman of Kalle GmbH, Senior Independent Director of Marks & Spencer Group plc and Chair, Exec Committee, Diversey Inc.

Vindi’s external appointments include Partner, Clayton Dubilier & Rice; Non-Executive Director, The Economist Newspaper Limited; Member, Holdingham International Advisory Board; Board Member, International Chamber of Commerce UK; Member, Governing Board of the Indian School of Business, Hyderabad; Member, Global Leadership Council of Saïd Business School, Oxford; Member, Indo UK CEO Forum, and Chair of the Board of Trustees, Marie Curie.

About Tracy Clarke

Tracy is currently Non-Executive Director and Chair of Remuneration at TP ICAP plc, Starling Bank, and the All England Netball Association. She is also Chair of a start-up called SchoolOnline and Advisor and Non-Executive Director at Acin Ltd.

Tracy brings considerable international banking, financial services, commercial, and leadership experience, having held a range of senior executive positions over 30 years at Standard Chartered Bank, where her last role was Private Bank CEO and Regional CEO, Europe & Americas. During her time at Standard Chartered she served as a director of Standard Chartered Bank UK, a Non-Executive Director of Standard Chartered First Bank in Korea, director of Zodia Holdings Limited and Zodia Custody Ltd. She also chaired the Supervisory Board of Standard Chartered Bank AG and Standard Chartered Yatirim Bankasi Turk A.S.

Tracy is an experienced remuneration committee chair and non-executive director. Her prior non-executive roles include Chair of the Remuneration Committees of Sky plc and Eaga plc and Non-Executive Director and Remuneration Committee member of Inmarsat plc. She has also served on the boards of the China Britain Business Council and TheCityUK.

About Vivienne Cox

Vivienne is currently an independent Non-Executive Director and Workforce Engagement Director at GSK.

Vivienne has wide experience of business gained in the energy, natural resources, and publishing sectors. She also has a deep understanding of regulatory organizations and government. Vivienne worked for BP plc for 28 years, in Britain and Continental Europe, in posts including EVP and CEO of BP’s gas, power, and renewable business and its alternative energy unit. Vivienne was previously a Non-Executive Director of BG Group plc and Rio Tinto plc, the Senior Independent Director of Pearson plc, Chairman of the Supervisory Board of Vallourec, and the Lead Independent Director at the UK Government’s Department for International Development.

Vivienne’s external appointments include Chair, Victrex plc; Non-Executive Director, Stena AB; Advisory Board Member, African Leadership Institute; VP, Energy Institute; Advisory Board Member, Montrose Associates; Investment Advisor, QantX Ventures; Chair, Rosalind Franklin Institute; Vice-Chair, Saïd Business School, Oxford and member of its Global Leadership Council, and Patron, Hospice of St Francis.

About Tobias Hestler

Tobias was appointed CFO Designate of Haleon in December 2021, having been CFO of the division since 2017. Before joining GSK, Tobias was the CFO at Sandoz – Novartis’ Generics Division. In 2010, he was named CFO for the former Novartis Consumer Health Division, a position that evolved into Tobias’ role as CFO for the Novartis OTC division. Earlier in his career, he held both local and global finance leadership roles at Novartis in the US, Germany, and Switzerland, including as Global Head of Finance for the Animal Health business, Global Controller for Sandoz, and CFO for Hexal.

About Deirdre Mahlan

Deirdre is Chair of the Audit Committee at Experian plc, Non-Executive Director at Kimberly-Clark Corporation, and Chair of the Audit Committee of The Duckhorn Portfolio, Inc.

Deirdre has deep finance and consumer product experience and is a qualified accountant. She held several senior finance and general management roles over her 27-year career at Diageo, including President of Diageo North America, CFO, Deputy CFO, Head of Tax and Treasury at Diageo plc, SVP, CFO at Diageo North America, and VP of Finance at Diageo Guinness USA. She has also held various senior finance roles in Joseph Seagram and Sons, Inc. and PwC.

About John Young

John has had an extensive career at Pfizer for over 34 years. He is currently the Group President and Special Adviser to the CEO of Pfizer following his previous role as CBO where he played an important role in cultivating the collaborations that led to the successful development and delivery of the Pfizer-BioNTech COVID-19 vaccine. John has led many large-scale transformations, including the closing of the joint venture with GSK to create a premier global consumer healthcare business in 2019. John has extensive healthcare, commercial and international experience.

About GSK

GSK is a science-led global healthcare company.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.